{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T15:19:15Z","timestamp":1789139955812,"version":"build-2803163510"},"reference-count":30,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,4,7]],"date-time":"2022-04-07T00:00:00Z","timestamp":1649289600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81903672"],"award-info":[{"award-number":["81903672"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014764","name":"China International Medical Foundation","doi-asserted-by":"publisher","award":["Z-2018-35-2003"],"award-info":[{"award-number":["Z-2018-35-2003"]}],"id":[{"id":"10.13039\/501100014764","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Microbiol."],"abstract":"<jats:p>Polymyxins including polymyxin B and colistin (polymyxin E) are considered the last resort for treating infections caused by carbapenem-resistant gram-negative bacteria. However, <jats:italic>in vitro<\/jats:italic> regrowth with the emergence of resistance during treatment is common. Polymyxin heteroresistance, particularly in <jats:italic>Acinetobacter baumannii<\/jats:italic> and <jats:italic>Klebsiella pneumoniae<\/jats:italic>, has been widely reported. This study was primarily performed to evaluate the prevalence of colistin heteroresistance in carbapenem-resistant <jats:italic>K. pneumoniae<\/jats:italic> (CR-KP) and the association between <jats:italic>in vitro<\/jats:italic> regrowth and heteroresistance. The mechanisms of colistin resistance and the ability of combination therapies to suppress resistance selection were further investigated. A population analysis profile (PAP) analysis showed that 69 (71.9%) of 96 CR-KP strains had colistin heteroresistance. Time-kill assays revealed that the colistin monotherapy could quickly eliminate the bacterial cells in strains without heteroresistance within the first 6 h. Conversely, it could initially reduce the number of cells in heteroresistant strains, but then regrowth occurred rapidly. Resistance screening at 12 and 24 h in the time-kill assays indicated that susceptible populations were killed, and regrowth was the exact result of the continued growth of resistant subpopulations. Colistin resistance in the regrowth subpopulations was mainly due to the overexpression of <jats:italic>phoPQ<\/jats:italic> and <jats:italic>pmrD<\/jats:italic>. Colistin combined with tetracyclines (tigecycline or minocycline) or aminoglycosides (amikacin or gentamicin) could effectively suppress the resistance selection and significantly elicit <jats:italic>in vitro<\/jats:italic> synergistic effects. These findings suggested that the combination therapy can be used to treat infections caused by CR-KP with colistin heteroresistance. Nevertheless, further <jats:italic>in vivo<\/jats:italic> studies considering drugs pharmacokinetics\/pharmacodynamics are needed to confirm these findings.<\/jats:p>","DOI":"10.3389\/fmicb.2022.868991","type":"journal-article","created":{"date-parts":[[2022,4,7]],"date-time":"2022-04-07T07:57:33Z","timestamp":1649318253000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":25,"title":["Heteroresistance Is Associated With in vitro Regrowth During Colistin Treatment in Carbapenem-Resistant Klebsiella pneumoniae"],"prefix":"10.3389","volume":"13","author":[{"given":"Yifan","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinqian","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lili","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukun","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenyi","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shining","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wentao","family":"Ni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhancheng","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,4,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1038\/s41564-019-0480-z","article-title":"Antibiotic combinations that exploit heteroresistance to multiple drugs effectively control infection.","volume":"4","author":"Band","year":"2019","journal-title":"Nat. Microbiol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"e02448","DOI":"10.1128\/mBio.02448-17","article-title":"Carbapenem-resistant Klebsiella pneumoniae exhibiting clinically undetected colistin heteroresistance leads to treatment failure in a murine model of infection","volume":"9","author":"Band","year":"2018","journal-title":"mBio"},{"key":"B3","doi-asserted-by":"publisher","first-page":"e2881","DOI":"10.1128\/mBio.02881-20","article-title":"Enterobacterales colistin heteroresistance is largely undetected among carbapenem-resistant in the United States.","volume":"12","author":"Band","year":"2021","journal-title":"mBio"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2020.106271","article-title":"Enhanced bacterial killing with colistin\/sulbactam combination against carbapenem-resistant Acinetobacter baumannii.","volume":"57","author":"Bian","year":"2021","journal-title":"Int. J. Antimicrob. Agents"},{"key":"B5","doi-asserted-by":"publisher","first-page":"5696","DOI":"10.1128\/AAC.03110-14","article-title":"MgrB inactivation is a common mechanism of colistin resistance in KPC-producing Klebsiella pneumoniae of clinical origin.","volume":"58","author":"Cannatelli","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"B6","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1038\/s41429-020-0289-2","article-title":"Deciphering colistin heteroresistance in Acinetobacter baumannii clinical isolates from Wenzhou.","volume":"73","author":"Chen","year":"2020","journal-title":"China. J. Antibiot."},{"key":"B7","doi-asserted-by":"publisher","first-page":"2307","DOI":"10.1007\/s00284-020-02074-4","article-title":"Colistin resistance and extensive genetic variations in PmrAB and PhoPQ in Klebsiella Pneumoniae isolates from South Korea.","volume":"77","author":"Cheong","year":"2020","journal-title":"Curr. Microbiol."},{"key":"B8","first-page":"M100","year":"2020","journal-title":"Performance Standards for Antimicrobial Susceptibility Testing; Twenty- sixth Informational Supplement."},{"key":"B9","doi-asserted-by":"publisher","first-page":"2666","DOI":"10.1093\/jac\/dkz257","article-title":"Efficacy of colistin alone and in various combinations for the treatment of experimental osteomyelitis due to carbapenemase-producing Klebsiella pneumoniae.","volume":"74","author":"Cr\u00e9mieux","year":"2019","journal-title":"J. Antimicrob. Chemother."},{"key":"B10","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1086\/511642","article-title":"Mutant selection window hypothesis updated.","volume":"44","author":"Drlica","year":"2007","journal-title":"Clin. Infect. Dis."},{"key":"B11","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1016\/j.cmi.2019.04.013","article-title":"Management of carbapenem-resistant Enterobacteriaceae infections.","volume":"25","author":"Durante-Mangoni","year":"2019","journal-title":"Clin. Microbiol. Infect."},{"key":"B12","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1128\/CMR.00058-14","article-title":"Antimicrobial heteroresistance: an emerging field in need of clarity.","volume":"28","author":"El-Halfawy","year":"2015","journal-title":"Clin. Microbiol. Rev."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4274\/mjima.2017.1","article-title":"Investigation of colistin heteroresistance and some factors affecting heteroresistance in carbapenem-resistant a. baumannii strains.","volume":"6","author":"Gazel","year":"2017","journal-title":"Mediterr. J. Infect. Microb. Antimicrob."},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.677720","article-title":"Current update on intrinsic and acquired colistin resistance mechanisms in bacteria.","volume":"8","author":"Gogry","year":"2021","journal-title":"Front. Med."},{"key":"B15","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1128\/AAC.00766-07","article-title":"Colistin heteroresistance in acinetobacter and its association with previous colistin therapy.","volume":"52","author":"Hawley","year":"2008","journal-title":"Antimicrob. Agents. Chemother."},{"key":"B16","doi-asserted-by":"publisher","first-page":"2897","DOI":"10.1007\/s11033-021-06307-y","article-title":"Mobilized colistin resistance (mcr) genes from 1 to 10: a comprehensive review.","volume":"48","author":"Hussein","year":"2021","journal-title":"Mol. Biol. Rep."},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2020.106065","article-title":"Colistin heteroresistance in Acinetobacter spp.: systematic review and meta-analysis of the prevalence and discussion of the mechanisms and potential therapeutic implications.","volume":"56","author":"Karakonstantis","year":"2020","journal-title":"Int. J. Antimicrob. Agents."},{"key":"B18","doi-asserted-by":"crossref","DOI":"10.1186\/2047-217X-1-18","article-title":"SOAPdenovo2: an empirically improved memory-efficient short-read de novo assembler.","volume":"1","author":"Luo","year":"2012","journal-title":"Gigascience."},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2019.02029","article-title":"Ceftazidime\/avibactam improves the antibacterial efficacy of polymyxin B against polymyxin B heteroresistant KPC-2-Producing Klebsiella pneumoniae and hinders emergence of resistant subpopulation in vitro.","volume":"10","author":"Ma","year":"2019","journal-title":"Front. Microbiol."},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01853-20","article-title":"Polymyxin B pharmacodynamics in the hollow-fiber infection model: what you see may not be what you get.","volume":"65","author":"Maynard","year":"2021","journal-title":"Antimicrob. Agents. Chemother."},{"key":"B21","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1093\/jac\/dkab122","article-title":"In vitro and in vivo synergistic effects of tigecycline combined with aminoglycosides on carbapenem-resistant Klebsiella pneumoniae.","volume":"76","author":"Ni","year":"2021","journal-title":"J. Antimicrob. Chemother."},{"key":"B22","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1093\/jac\/dkl512","article-title":"In vitro pharmacodynamics of colistin against Acinetobacter baumannii clinical isolates.","volume":"59","author":"Owen","year":"2007","journal-title":"J. Antimicrob. Chemother."},{"key":"B23","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1093\/jac\/dku323","article-title":"The mgrB gene as a key target for acquired resistance to colistin in Klebsiella pneumoniae.","volume":"70","author":"Poirel","year":"2015","journal-title":"J. Antimicrob. Chemother."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1093\/jac\/dkn425","article-title":"In vitro pharmacodynamics of colistin against multidrug-resistant Klebsiella pneumoniae.","volume":"62","author":"Poudyal","year":"2008","journal-title":"J. Antimicrob. Chemother."},{"key":"B25","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1007\/s12275-021-0610-1","article-title":"Detection of colistin-resistant populations prior to antibiotic exposure in KPC-2-producing Klebsiella pneumoniae clinical isolates.","volume":"59","author":"Seo","year":"2021","journal-title":"J. Microbiol."},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1128\/Spectrum.00152-21","article-title":"Combined effect of Polymyxin B and tigecycline to overcome heteroresistance in carbapenem-resistant Klebsiella pneumoniae.","volume":"9","author":"Tian","year":"2021","journal-title":"Microbiol. Spectr."},{"key":"B27","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1128\/AAC.04037-14","article-title":"Genomic and transcriptomic analyses of colistin-resistant clinical isolates of Klebsiella pneumoniae reveal multiple pathways of resistance.","volume":"59","author":"Wright","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"B28","doi-asserted-by":"publisher","first-page":"2657","DOI":"10.2147\/IDR.S314490","article-title":"Molecular mechanism of polymyxin resistance in multidrug-resistant Klebsiella pneumoniae and Escherichia coli isolates from Henan Province. China: a multicenter study","volume":"14","author":"Yan","year":"2021","journal-title":"Infect. Drug Resist."},{"key":"B29","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1016\/j.tibs.2019.06.002","article-title":"Genetic and biochemical mechanisms for bacterial lipid a modifiers associated with polymyxin resistance.","volume":"44","author":"Zhang","year":"2019","journal-title":"Trends Biochem. Sci."},{"key":"B30","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1093\/jac\/dkw377","article-title":"Polymyxin monotherapy or in combination against carbapenem-resistant bacteria: systematic review and meta-analysis.","volume":"72","author":"Zusman","year":"2017","journal-title":"J. Antimicrob. Chemother."}],"container-title":["Frontiers in Microbiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmicb.2022.868991\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,7]],"date-time":"2022-04-07T07:57:45Z","timestamp":1649318265000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmicb.2022.868991\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,7]]},"references-count":30,"alternative-id":["10.3389\/fmicb.2022.868991"],"URL":"https:\/\/doi.org\/10.3389\/fmicb.2022.868991","relation":{},"ISSN":["1664-302X"],"issn-type":[{"value":"1664-302X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,7]]},"article-number":"868991"}}